Related Experiment Video

Updated: Jun 29, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Gut Microbiota: Potential Therapeutic Target for Sickle Cell Disease Pain and Complications

Tarimoboere Agbalalah1,2, Doofan Bur2, Ezinne JaneFrances Nwonu2

  • 1Department of Anatomy, Faculty of Basic Medical Sciences, Baze University, Abuja, Nigeria.

Anemia
|March 27, 2024
PubMed

Insights

Sickle cell disease (SCD) management may improve with gut bacteria like Akkermansia muciniphila and Roseburia spp. Supplementation shows promise in reducing chronic pain by addressing gut dysbiosis and inflammation in SCD patients.

Area of Science:

  • Microbiome research
  • Gastroenterology
  • Hematology

Background:

  • Sickle cell disease (SCD) incidence rose 41.4% from 2000-2021, increasing morbidity and mortality.
  • Gut microbiota dysbiosis is linked to SCD complications, especially chronic pain, due to altered proinflammatory bacteria.
  • Specific bacterial alterations in the gut microbiome are increasingly recognized as key factors in SCD pathophysiology.

Purpose of the Study:

  • To explore the therapeutic potential of Akkermansia muciniphila and Roseburia spp. in managing SCD.
  • To emphasize the roles of these bacteria in maintaining gut barrier integrity, reducing inflammation, and modulating immune responses.
  • To investigate novel avenues for sustainable SCD management through microbiome modulation.

Main Methods:

  • A comprehensive literature search was conducted up to November 2023.
  • Databases used included PubMed, MEDLINE, and Google Scholar.
  • The search focused on SCD pathophysiology, gut microbiota, specific bacterial species, pain, dysbiosis, and butyrate therapy.

Main Results:

  • Supplementation with Akkermansia muciniphila and Roseburia spp. demonstrates potential in alleviating chronic pain associated with SCD.
  • These interventions address gut dysbiosis, offering a promising approach for sustainable SCD management.
  • The findings highlight the significant role of the gut microbiome in SCD and support personalized treatment strategies.

Conclusions:

  • Akkermansia muciniphila and Roseburia spp. supplementation presents a promising avenue for managing SCD complications, particularly chronic pain.
  • This approach could reduce reliance on conventional treatments and enhance patients' quality of life.
  • Further clinical trials are essential to fully realize the therapeutic benefits of these gut bacteria in SCD.
Abstract

More Related Videos

Murine Fecal Isolation and Microbiota Transplantation07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.0K
Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases07:45

Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases

Published on: September 1, 2017

12.1K

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
127
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
436
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.7K